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Abstract
Amyotrophic lateral sclerosis (ALS) is a progressive fatal neurodegenerative disease characterised by loss of motor neurons
that currently has no cure. Omega-3 polyunsaturated fatty acids, such as eicosapentaenoic acid (EPA), have many health
benefits including neuroprotective and myoprotective potential. We tested the hypothesis that a high level of dietary EPA
could exert beneficial effects in ALS. The dietary exposure to EPA (300 mg/kg/day) in a well-established mouse model of ALS
expressing the G93A superoxide dismutase 1 (SOD1) mutation was initiated at a pre-symptomatic or symptomatic stage,
and the disease progression was monitored until the end stage. Daily dietary EPA exposure initiated at the disease onset did
not significantly alter disease presentation and progression. In contrast, EPA treatment initiated at the pre-symptomatic
stage induced a significantly shorter lifespan. In a separate group of animals sacrificed before the end stage, the tissue
analysis showed that the vacuolisation detected in G93A-SOD1 mice was significantly increased by exposure to EPA.
Although EPA did not alter motor neurone loss, EPA reversed the significant increase in activated microglia and the
astrocytic activation seen in G93A-SOD1 mice. The microglia in the spinal cord of G93A-SOD1 mice treated with EPA showed
a significant increase in 4-hydroxy-2-hexenal, a highly toxic aldehydic oxidation product of omega-3 fatty acids. These data
show that dietary EPA supplementation in ALS has the potential to worsen the condition and accelerate the disease
progression. This suggests that great caution should be exerted when considering dietary omega-3 fatty acid supplements
in ALS patients.
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Introduction
Amyotrophic lateral sclerosis (ALS) is the most common form of
motor neuron disease. It is a neurodegenerative disease associated
with loss of motor neurons in the spinal cord, brain stem and
motor cortex, resulting in significant disability which ultimately
leads to paralysis and death [1]. The median survival is 3–5 years
from the onset of symptoms [2]. Currently, there is no cure for
ALS and the only drug currently available is riluzole, which can
only extend the lifespan of ALS patients by a few months [3].
Therefore, there is the uttermost need to find more effective
therapies that will be beneficial to ALS patients.
Omega-3 polyunsaturated fatty acids (PUFAs) are natural
compounds which have been associated with significant health
benefits [4]. Furthermore, our laboratory and others have reported
data which suggest that the long-chain omega-3 PUFAs
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)
have significant neuroprotective potential [5,6,7]. In aged rat
brain, dietary supplementation with a mixture of EPA and DHA
reverses age-related decreases in nuclear receptors and increases
neurogenesis [8]. The neuroprotective effects of EPA and DHA
can potentially occur through a variety of mechanisms, including a
reduction in oxidative stress, excitotoxicity and neuroinflamma-
tion, and activation of anti-apoptotic pathways [9,10,11], process-
es which are very relevant in the context of the pathophysiology of
ALS [12].
It is interesting to note that abnormalities in lipids have been
linked with ALS. A number of studies have shown hyperlipidaemia
to be a typical feature of ALS, and also positively correlated with
disease progression and survival [13,14]. Furthermore, a recent
report showed that a high-fat diet in transgenic mice partially
reversed the expression of markers of muscle denervation, delayed
motor neuron death and also extended the lifespan of mice by
20% [15].
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The aim of the present study was to explore the potential
neuroprotective effects of EPA in a transgenic SOD1 mouse model
of ALS. The G93A-SOD1 mice, that overexpress the human
mutant SOD1 (Gly-93-Ala substitution) gene, exhibit pathological
features that are very similar to human ALS [16,17], and have
been previously used in our laboratories [18,19]. We investigated
both the effect of treatment initiated at the disease onset or at a
pre-symptomatic stage. We chose a daily dose of EPA of 300 mg/
kg, which is in the range of doses of omega-3 PUFA reported to be
neuroprotective for the central nervous system [5,8]. The effects of
the treatment were investigated using behavioral and histological




Procedures involving animals and their care were conducted
according to the Mario Negri’s institutional guidelines, that are in
compliance with national (D.L. no. 116, G.U. suppl. 40, Feb. 18,
1992, Circular No.8, G.U., 14 luglio 1994) and international laws
and policies (EEC Council Directive 86/609, OJ L 358, 1 Dec.12,
1987; NIH Guide for the Care and use of Laboratory Animals,
U.S. National Research Council, 1996). All the experiments and
the protocol proposed in the projects were examined first by
Institutional Ethical Committee and then sent to the Italian
Ministry of Health for authorization. The mice were bred and
maintained in a SPF environment. Animals with substantial motor
impairment had food on the cage bottom and water bottles with
long drinking spouts. The survival time was defined as the time
when the animals were unable to right themselves within 30 s after
being placed on either side. The animals were deeply anesthetized
with Equithesin and then sacrificed by decapitation before
proceeding to the dissection of tissues or to undergo intracardiac
perfusion if tissues were needed for use in immunohistochemistry.
Animals and treatment
Female adult transgenic G93A-SOD1 mice on a C57BL/
6JOlaHsd (C57/G93A) or a 129S2/SvHsd (129Sv/G93A) genetic
background and their corresponding non-transgenic littermates
were used in this study. The two G93A-SOD1 strains differ in the
disease onset and duration [20]. Male mice are normally used for
breeding to maintain the colony. All mice were maintained at a
temperature of 2161uC with a relative humidity of 55610% and
12 h of light, and food and water were available ad libitum.
Animals were fed either a standard rodent powdered diet
(control diet) or a diet supplemented with the EPA-enriched oil
Incromega SE7010R (Croda Healthcare, U.K.) which provided
an average intake of 300 mg/kg/day EPA (EPA diet). Incromega
SE7010R contains 70% EPA and around 10% DHA, both in an
ethyl ester forms, and the rest represented by other components.
The food was replaced daily. Mice were housed in cages (n = 3–4
per cage) which contained a purpose built plastic box containing 4
holes for powdered food access, with minimal food spillage. The
amount of food eaten for each cage was recorded twice weekly and
the data divided for the number of mice present in the cage. In a
pilot bioavailability study we assessed whether the addition of
EPA-oil to the diet or the oral gavage once a day with EPA-
enriched oil to provide 300 mg/kg, led to comparable changes in
plasma fatty acids (n = 5 animals per group). At the end of 7 days
exposure to EPA, animals were killed and the plasma collected and
frozen until lipid analysis.
In one experiment C57BL/6 G93A-SOD1 mice (n = 16 each
group) received EPA-enriched or control diet daily starting at
disease onset (16 weeks age). In another experiment both G93A-
SOD1 mouse strains (n = 14 animals each group) were treated
daily with control or EPA-enriched diet, starting at a presymp-
tomatic stage (12 weeks age for the 129Sv strain and 14 weeks age
for the C57BL/6 strain).
Disease progression assessment
Disease progression assessment was performed three times a
week from the start of the experiment, by an operator blinded to
the treatment. The parameters measured included body weight,
locomotor activity on the Rotarod, grip strength and the hindlimb
extension reflex as previously described [20]. The disease onset
was determined by 1) a decrease in 3–5% body weight in
comparison to the animal’s maximum weight, 2) a reduction in the
Table 1. Oral administration of EPA increases plasma EPA levels in G93A-SOD1 mice.
Fold change
Mouse strain Fatty acid (% of total) Control diet EPA gavage EPA diet EPA gavage EPA diet
C57BL6 mice EPA 0.360.1 1.960.2 * 2.060.1 * +6.3 +6.7
DHA 3.160.9 5.360.4 * 6.860.6 * +1.7 +2.2
DHA/EPA 10.962.5 2.860.4 * 3.460.4 * 23.9 23.2
Total n-3 PUFA 45.062.0 44.262.3 43.461.8 +1.0 +1.0
Total n-6 PUFA 45.062.0 44.262.3 43.461.8 +1.0 +1.0
Total PUFA 49.062.9 52.662.5 53.162.2 +1.1 +1.1
129Sv mice EPA 0.460.1 1.560.5 * 2.360.3 * +3.8 +5.8
DHA 3.761.3 4.961.3 * 6.360.7 * +1.3 +1.7
DHA/EPA 9.062.4 3.661.6 * 2.860.2 * 22.5 23.2
Total n-3 PUFA 4.861.6 7.361.4 * 9.361.0 * +1.5 +1.9
Total n-6 PUFA 46.563.7 48.561.7 46.860.5 +1.0 +1.0
Total PUFA 51.364.5 55.862.7 56.161.3 +1.1 +1.1
Mice administered with either a single bolus dose of EPA (300 mg/kg, p.o.) or fed with an EPA enriched diet (300 mg/kg/day) for 7 days had higher levels of EPA and
DHA in their plasma than mice fed on the control diet.
doi:10.1371/journal.pone.0061626.t001
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hind limb extension reflex when lifted by the tail, and 3) a decrease
of around 10% in maximal Rotarod performance and/or grip
strength. The survival time was defined as the time when the
animals were unable to right themselves within 30 s after being
placed on either side.
Lipid analysis
The plasma and the spinal cord and brain tissue were harvested
and frozen at 280uC until analysis. The plasma fatty acids were
measured by the Nutrition Analytical Service (University of
Stirling, Scotland). The tissue lipid analysis was carried out as
previously described [21]. Lipids were extracted using the method
of [22] with 0.01% w/v 2,6-di-tert-butyl-p-cresol (butylated
hydroxytoluene, BHT) added as an antioxidant, and total
phospholipids were then isolated by thin layer chromatography
[23]. The fatty acid composition of phospholipids was measured
after transesterification with 14% boron trifluoride in methanol
and individual fatty acids identified by gas chromatography
coupled to mass spectrometry (Agilent 6890 gas chromatograph
connected to an Agilent 5973 mass selective detector, Agilent
technologies, U.S.A.) using a Supelcowax 10 capillary column
(30 m60.25 mm60.25 mm), as described previously [21]. Lipid
identity was confirmed by retention times compared to known
standards and mass spectra comparison to the National Institute of
Standards and Technology database. Quantification was per-
formed on selected ion peak area by ChemStation software
(Agilent Technologies, U.S.A). Corrections were made for
variations in the detector response and values of detected fatty
acids were normalised to 100% and expressed as mol%.
Histology
For the histological analysis, four groups of 4 mice each were
treated from 14 weeks of age for 6–7 weeks with the following
regime: 1) Non-transgenic wild type mice on control diet, 2)
G93A-SOD1 mice on control diet, 3) Non-transgenic wild type
mice on EPA diet, and 4) G93A-SOD1 mice on EPA diet.
When the G93A-SOD1 mice on the control diet exhibited a
50% reduction in the Rotarod performance and body weight loss,
all the mice, including those on the EPA diet, were sacrificed and
perfused with 4% paraformaldehyde, and the tissues were post-
fixed as previously described [20].
The spinal cords were allocated into four batches, each
containing one animal from each treatment group. The lumbar
spinal cord segments were cut into 15 mm cryostat sections, stained
and analysed by a blinded operator. Sections were allowed to dry
for at least an hour before storage at 280uC until further
processing.
a) Histochemistry. To analyze the gross structural morphol-
ogy, the spinal cord sections were stained for haematoxylin
and eosin (H&E) using a standard protocol. Briefly, slides
(stained together in batches containing tissue from an animal
from each treatment group) were removed from 280uC and
allowed to defrost for 5 min before a wash in tap water for
30 s then incubation in haematoxylin (700 ml/slide) for
2 min. Sections were washed in tap water for 30 s,
differentiated in acid alcohol for 2 s then washed again in
tap water for 30 s. After incubation with 2% calcium
bicarbonate for 2 s and a wash in tap water for 30 s, sections
were incubated in 1% eosin for 30 s, followed by 30 s wash in
tap water. Sections were dehydrated in ascending alcohol
concentration for 30 s each, cleared in 2 changes of
Histoclear for 1 min each, then mounted with Histomount.
Images were captured using a Zeiss Axioskop microscope and
the Axiovision program.
b) Immunohistochemistry. To analyze for cellular changes,
the spinal cord sections were immunostained with the
following antibodies: NeuN (neuronal marker, Chemicon,
1:500), GFAP (astrocytic marker, Dako, 1:1000), Iba1
(activated and non-activated microglial marker, Wako,
1:1000), OX42 (activated microglial marker, Serotec,
1:500), ChAT (motor neuron marker, Chemicon, 1:100), 4-
hydroxy-hexenal (4-HHE) (lipid oxidation marker, JaICA,
1:100).
Sections (each batch of staining containing tissue from one
animal from each treatment group) were removed from 280uC
and allowed to defrost for 5 min. After 365 min washes in
phosphate buffered saline (PBS), sections were incubated overnight
in the chosen antibodies at room temperature. The next day,
sections were washed 365 min in PBS then incubated in the
secondary antibodies (donkey anti-goat, -mouse, -rabbit Alexa
Fluor 488 or 568; final concentration 1:1000) for 2.5 h at room
temperature. After 365 min washes in PBS, sections were
coverslipped in Vectashield containing the DAPI stain, to visualize
the nuclei. Fluorescent Nissl staining of spinal cord sections
involved incubation with NeuroTrace green-fluorescent Nissl stain
for 20 min (N-21480, Molecular Probes, Invitrogen; 1:100) [24].
Six to eight sections per animal were captured on a Zeiss
microscope using the Axiovision v4.6 program. To avoid capture
variability, each batch of immunostaining was captured in the
same session using the same settings.
Histological quantitative analysis
Six to eight sections per animal per group were analyzed in
blind (to either treatment or disease) using Axiovision v4.8. For the
analysis of vacuolization in the H&E staining set, a
500 mm6500 mm square (250,000 mm2) was placed over both
the left and right dorsal and ventral horns. The areas of
vacuolisation were recorded, and the left and right sides were
averaged per section, with the data plotted as percentage of the
250,000 mm2 of area analyzed per one side of the spinal cord. In
the analysis of intensity in immunostained sections, a
100 mm6100 mm square (10,000 mm2) was placed over the ventral
horn. The number of cells with positive immunostaining and
positive DAPI stained nuclei was recorded. The values from the
left and right sides were averaged per section, with the data plotted
as average intensity or number of positive cells per 10,000 mm2 of
area analyzed per one side of the spinal cord. In the analysis of 4-
HHE staining, microglia (i.e. Iba1 immunopositive cells) were
drawn around (30 cells in the ventral horn) using the Axiovision
program, which calculated the intensity of the 4-HHE immuno-
staining. Ten non-immunopositive areas directly adjacent to the
Iba1 immunopositive cells were drawn around, to provide the
background staining signal and thus provide a value for
normalization purposes.
Figure 1. G93A-SOD1 C57BL/6 mice with dietary EPA at the symptomatic stage of the disease do not have a significantly different
development of the disease compared to animals on the control diet. (A) Consumption of food is slightly increased when diet is enriched
with EPA. (B) The body weight of mice was not affected as the disease evolves (C) Survival and (D) disease duration were not affected by dietary EPA.
(E) The Rotarod and (F) The grip strength were not affected by dietary EPA.
doi:10.1371/journal.pone.0061626.g001
Dietary EPA Accelerates ALS Disease
PLOS ONE | www.plosone.org 4 April 2013 | Volume 8 | Issue 4 | e61626
Dietary EPA Accelerates ALS Disease
PLOS ONE | www.plosone.org 5 April 2013 | Volume 8 | Issue 4 | e61626
Measurement of nitrotyrosine
The measurement of nitrotyrosine (NT) levels was carried out
according to the protocol previously described [25]. Briefly,
aliquots (2 mg protein) of total spinal cord homogenates from
G93A-SOD1 mice and non transgenic littermates fed with control
or EPA diet were loaded on nitrocellulose membrane, Trans-Blot
Transfer Medium (Bio-Rad), by vacuum deposition on the Bio-
Dot SF blotting apparatus (Bio-Rad). Membranes were probed
over-night with the anti-3-NT monoclonal antibody (clone
HM.11; Hycult Biotechnology) diluted 1:1,000 and then with
anti-mouse peroxidase-conjugated secondary antibody (Santa
Cruz Biotechnology). Blots were developed by the ECL technique
(homemade) and densitometric analysis of autoradiographic bands
was carried out using a computer-assisted image analysis system
(QuantityOne, BioRad). Immunoreactivity was normalized to the
actual amount of protein loaded on the membrane as detected
after Red Ponceau staining.
Statistical analysis
All the data were plotted on graphs or in Table as means 6
S.E.M. All the behavioural data were statistically analysed with
GraphPad Prism (v5.03) software (GraphPad Software, Inc.) and
all histological data were statistically analysed with SigmaStat
(v3.5) software (Systat Software Inc.). The statistical significance
for survival, disease onset and duration data was analyzed with the
Gehan-Breslow-Wilcoxon test. The statistical significance for the
other behavioral and biochemical data and the immunostaining
was analyzed by two way single or repeated-measures ANOVA
followed by Tukey’s or Bonferroni’s post-hoc test.
Results
1) Increased plasma EPA content after oral gavage or
dietary supplementation with EPA
In a first part of the study, focused on the bioavailability of EPA,
we determined the level of EPA in plasma following free dietary
intake, which provided a less invasive mode of administration, as
compared to oral gavage. The dietary intake of EPA for 7 days by
G93A-SOD1 C57BL/6 mice or 129Sv mice increased the plasma
levels of EPA by 6.7 or 5.8 fold, respectively, when compared to
the control diet (Table 1). An increase of 6.3 fold in plasma EPA
was detected when G93A-SOD1 C57BL/6 mice received a single
daily bolus of EPA at 300 mg/kg body weight by gavage and a
smaller increase (3.8 fold) was seen after gavage in 129Sv mice
(Table 1). Furthermore, the increases in plasma DHA seen after
free dietary intake were also comparable (even slightly higher) than
the increases seen after gavage, in the two strains. For example, the
increase in C57BL/6 mice was 2.2 vs. 1.7 fold after dietary intake
and gavage, respectively. The values in 129Sv mice were 1.7 and
1.3, respectively. This confirmed the adequate bioavailability of
EPA using free dietary intake.
2) Dietary EPA administered at disease onset did not
affect the course of motor deficit nor the survival length
In the first experiment, we initiated the treatment with EPA
300 mg/kg/day at disease onset, in G93A-SOD1 C57BL/6 mice.
During treatment, there was a slight non-significant increase in
food intake in the EPA diet group compared to the control diet
group (Fig. 1A). However, there were no significant differences in
the body weight loss during the development of the disease
between the two treatment groups of G93A-SOD1 mice (Fig. 1B).
Furthermore, no significant changes were observed in both
survival and disease duration (Fig. 1C–D). There were no
differences in the performance of the transgenic mice exposed to
the control EPA diet, in the functional tasks of Rotarod and grip
strength (Fig. 1E–F). Similar data were seen when the experiment
was performed in 129Sv mice (Fig. S1). These observations
indicated that in G93A-SOD1 mice, when dietary exposure to
high EPA intake was initiated at the onset stage of the disease, the
PUFA had no obvious impact on the disease process.
3) Dietary EPA intake at pre-symptomatic stage of ALS
disease accelerates disease progression
The lack of effects seen when the treatment was initiated at
disease onset led us to hypothesize that a longer exposure, in the
transgenic animals with the slower disease evolution, may provide
a better opportunity to characterize a neuroprotective potential.
Therefore, treatment was initiated at a pre-symptomatic stage (14
weeks of age). The amount of diet eaten by G93A-SOD1 mice
when exposed to EPA enrichment at a pre-symptomatic stage of
the disease was significantly greater overall, during the experiment,
than by G93A-SOD1 mice on the standard control diet, although
there was a certain variability (Fig. 2A). Therefore, EPA appeared
to increase the appetite of the animals. However, unexpectedly, in
spite of an increase in food intake, there was a significant higher
body weight loss in G93A-SOD1 mice on the EPA diet compared
to the control diet group (Fig. 2B).
The dietary intake of EPA (300 mg/kg/day) by G93A-SOD1
C57BL/6 mice significantly enhanced the rate of disease
progression, indicated by parameters such as survival (loss of
righting reflex) and disease duration (Fig. 2C–D). Furthermore, the
functional tests on the Rotarod and the hind limb extension reflex
showed a significant reduction in the animals’ ability to use their
hind limbs, when the EPA group was compared to the control diet
group (Fig. 2E–F). Interestingly, no significant difference in disease
onset (Fig. 2G) and grip strength (Fig. 2H) was seen between EPA
treated and control animals. This data suggest that G93A-SOD1
mice at the pre-symptomatic stage of the disease when fed the EPA
diet have an accelerated disease progression. A similar trend was
observed in G93A-SOD1 129Sv mice treated with 300 mg/kg/
day starting the treatment at pre-symptomatic stage (12 week age)
(Fig. S2).
Therefore, quite unexpectedly, this indicated overall that the
prolonged exposure to the EPA diet and the initiation of the
exposure to this fatty acid at a pre-symptomatic stage, led to an
accelerated disease progression. The lack of significant difference
in the grip strength suggests that the EPA diet could influence the
disease progression mostly in the hind limbs, which are more
affected in respect to the forelimbs.
4) Dietary EPA is linked to intense vacuolisation
In order to identify the changes which may underlie the disease
worsening seen after EPA exposure at the pre-symptomatic stage,
described above, we treated G93A-SOD1 C57BL/6 animals for
Figure 2. G93A-SOD1 C57BL/6 mice treated with dietary EPA at the pre-symptomatic stage of ALS have an accelerated
development of the disease compared to G93A-SOD1 mice on the control diet. (A) Consumption of food is increased in animals on the EPA
enriched diet. (B) The body weight of mice with EPA diet decreases as the disease evolves. (C) Survival and (D) disease duration are both reduced with
dietary EPA. (E) The Rotarod and (F) Hindlimb extension reflex are both affected by dietary EPA. (G) The rate at which the disease starts is not affected
by dietary EPA. (H) The grip strength was not affected by dietary EPA.
doi:10.1371/journal.pone.0061626.g002
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several weeks with EPA, but we sacrificed them before the
terminal stage, for tissue analysis. First, H & E staining was carried
out, to assess the crude morphology, and this revealed clearly
visible vacuoles in the lumbar spinal cord of G93A-SOD1 mice
compared to the wild-type littermate mice (Fig. 3A–H). Interest-
ingly, in the control diet groups, the G93A-SOD1 mice only
showed a significant increase in vacuolisation in the ventral horn
and not in the dorsal horn, when compared with the wild-type
littermate mice. (Fig. 3A–B). The analysis showed that there was a
further marked and significant increase in vacuolisation within the
dorsal and ventral horn of the G93A-SOD1 mice treated with the
EPA diet, compared to the control diet (Fig. 3I–J). Furthermore,
the cells appeared more intensely eosinophilic in the G93A-SOD1
mice EPA treatment compared to the other groups (Fig. 3C–D,
G–H).
5) Dietary EPA is not associated with significant
alterations in neuronal cells
To determine the neuronal changes in the spinal cord,
immunohistochemistry and quantitative analysis was carried out
as previously described [26]. Neurons and more specifically motor
neurons were visualized with the immunomarkers NeuN and
ChAT, respectively. There was a significant reduction in both
NeuN and ChAT immunopositive cell counts in G93A-SOD1
C57BL/6 mice compared to wild type littermate controls (Fig. 4A–
N). In the groups on dietary EPA, there was no significant
difference in neuronal staining in either the wild type littermates or
G93A-SOD1 mice groups when compared to the groups on the
control diet (Fig. 4M–N).
The axons of motor neurons in the ventral roots, which can be
visualized using ChAT immunostaining, showed a significant
decrease in the axon diameter size in the G93A-SOD1 mice
compared to the wild type littermate mice, in both the control and
EPA diet groups (Fig. 5A–E). However, there was no significant
difference between G93A-SOD1 mice on either the EPA or the
control diet (Fig. 5A–E).
6) Dietary EPA leads to alterations in glial cells
To determine if the non-neuronal cells, i.e. astrocytes and
microglia, are involved in the deleterious effect of dietary EPA,
immunostaining and quantitative analysis of non-neuronal cells
was carried out.
a) Astrocytes. Astrocytes were visualized using GFAP as a
marker, as previously [27]. There was a significant increase in
the number and staining intensity of GFAP immunopositive
cells present in the ventral horn of G93A-SOD1 mice
compared to the wild-type littermates (Fig. 6A–F, M–N).
However, after the EPA diet, the number and staining
intensity of GFAP immunopositive cells in G93A-SOD1 mice
was significantly lower than in the G93A-SOD1 mice on the
control diet, with no statistically significant differences in
comparison to the wild type littermates of either treatment
groups (Fig. 6M–N).
b) Microglia. Microglia were visualized using the immuno-
markers Iba1 (activated and non-activated form) and OX42
(activated form) as previously [27]. There was a significant
increase in the number of Iba1 and OX42 immunopositive
cells in the ventral horn of G93A-SOD1 C57BL/6 mice
compared to the wild type littermate mice, on the control diet
(Fig. 7A–F, M). Interestingly, there was also a significant
reduction in the number of Iba1 and OX42 immunopositive
cells present in the ventral horn of G93A-SOD1 mice treated
with the EPA diet compared to the G93A-SOD1 mice on the
control diet (Fig. 7M–N).
These data suggested that the dietary intake of EPA could
significantly reduce the levels of reactive astrogliosis and microglial
reaction in the lumbar spinal cord of G93A-SOD1 mice.
7) Dietary EPA increases the lipid peroxidation in
microglia
To assess lipid-linked oxidation processes, the major lipid
peroxidation product of omega-3 fatty acids, the immunostaining
marker 4-hydroxy-2-hexenal (4-HHE) was used [28]. The
expression of the oxidative marker 4-HHE was present at the
highest level within the microglia, and not in neurons or astrocytes
(data not shown). Within the microglia, the 4-HHE immunostain-
ing level was significantly higher in the G93A-SOD1 mice on EPA
diet compared to the control diet (Fig. 8A–M). Interestingly, the 4-
HHE immunostaining level between the G93A-SOD1 mice and
wild type littermates on the control diet was not significantly
different (Fig. 8M).
8) Dietary EPA reduces the level of nitrotyrosine (NT) in
lumbar spinal cord
In order to examine whether the deleterious effect of dietary
EPA could be due to an increase in protein oxidation, we
determined the level of nitrotyrosine in the spinal cord of G93A-
SOD1 mice fed with EPA from the pre-symptomatic stage in
comparison to control standard diet fed mice. Although we did not
observe a significant increase of nitrotyrosine in G93A-SOD1 mice
compared to non-transgenic mice, the EPA diet significantly
reduced the levels of NT in G93A-SOD1 mice in respect to
control diet fed transgenic mice (Fig. 9).
9) Dietary EPA and tissue lipid content changes
To assess the impact of the EPA diet on the tissue lipid
composition, we analyzed extracts of both spinal cord and brain
from wild type and transgenic G93A-SOD1 mice that were
exposed to the diet for the same period as the animals used for
histological analysis. The results showed that the supplementation
with EPA led to very modest changes in spinal cord tissue EPA
and DHA (only a significant increase in DHA in transgenic
animals). In contrast, the treatment led to more marked increases
in EPA and DHA in brain tissue, in both wild type (EPA and
DHA) and G93A-SOD1 mice (DHA only). There were corre-
sponding decreases in arachidonic acid (AA) in both wild type and
transgenic animals (Fig. 10).
Discussion
The aim of the present study was to establish whether the long-
chain omega-3 fatty acid EPA has a neuroprotective potential in
Figure 3. G93A-SOD1 C57BL/6 mice treated with EPA at the pre-symptomatic stage of the disease have an increase in vacuolization
in the spinal cord. (A–B) Wild type littermates on the control diet have very sparse vacuoles within the spinal cord. (C–D) G93A-SOD1 mice on the
control diet have vacuoles predominantly in the ventral horn. (E–F) Wild type littermates on the EPA diet have a slight increase in vacuoles within the
spinal cord. (G–H) G93A-SOD1 mice on the EPA diet have a marked increase in vacuoles in the dorsal and ventral horn. (I–J) Quantitative analysis of
vacuolisation in the spinal cord. Scale bar = 50 mm.
doi:10.1371/journal.pone.0061626.g003
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ALS. The model chosen to test this was the extensively used
G93A-SOD1 transgenic mouse model [18]. EPA either supple-
mented in the diet or as an oral bolus administration provided
excellent bioavailability of the fatty acid. When the EPA-
supplemented diet (a regime preferred for its non-invasive nature)
was provided to animals at the disease onset, the treatment had no
Figure 4. Neuronal loss in G93A-SOD1 C57BL/6 mice treated with EPA at the pre-symptomatic stage of the disease is not affected
by treatment. The G93A-SOD1 mice have significantly fewer neurons compared to the control wild type littermates, when the tissue is labelled with
ChAT (motor neuron marker, red) or NeuN (general neuronal marker, green) (A–L). Nuclei are stained with DAPI (blue). No significant difference in cell
number was observed between the EPA and control diet groups (M). Scale bar = 100 mm.
doi:10.1371/journal.pone.0061626.g004
Figure 5. Motor neuron axonal loss in G93A-SOD1 C57BL/6 mice treated with EPA at the pre-symptomatic stage of the disease is
not affected by dietary EPA. ChAT-labelled motor neuron axons can be observed (A–D). There are significantly fewer axons in G93A-SOD1 mice
compared to the wild type littermates. No significant difference in the number of axons was observed between the EPA and control diet groups.
Scale bar = 100 mm.
doi:10.1371/journal.pone.0061626.g005
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significant impact on disease onset and survival, nor did it improve
neurological score. Unexpectedly, when dietary EPA was provided
at a pre-symptomatic stage, the fatty acid decreased survival.
Using histological and immunocytochemical analysis, the spinal
cord tissue from G93A-SOD1 transgenic animals showed vacu-
olisation. However, the vacuolisation was amplified in the tissue of
animals receiving EPA. A loss of neurons was also observed in the
tissue of transgenic animals, but this loss was not exacerbated by
dietary EPA, and neither was the significant motor neuron axonal
loss, which was already apparent in transgenic animals. An
analysis of early changes in neuronal synaptic markers would add
more information on the impact of the treatment with EPA on the
neurodegenerative mechanisms involved at an early stage of the
disease. In accord with many reports in the literature, we found
significant alterations in glial cells in G93A-SOD1 mice, support-
ing the concept of non-cell autonomous disease [29,30,31,32].
Microglial activation and the appearance of reactive astrocytes
have been described in ALS [11,27,28]. The expression of
mutated SOD1 in astrocytes leads to neurotoxicity [33,34], and
astrocytes amplify pathogenetic processes, such as the oxidative
stress. They up-regulate the production of nitric oxide, increasing
nitrative stress. Interestingly, although in our study the nitrotyr-
osine production was not markedly affected by the disease, there
was a small but significant reduction in the level of nitrotyrosine
detected in the spinal cord of G93A-SOD1 mice receiving dietary
EPA compared to the transgenic animals receiving the control
diet. This effect could be explained by the reduced number of
astrocytes observed in G93A-SOD1 mice on dietary EPA.
Whether and how this could relate to the exacerbation of the
disease symptoms is unknown. Immunostaining for a toxic lipid
peroxidation marker specific for omega-3 fatty acids, 4-hydroxy-2-
hexenal (4-HHE), showed a higher signal in microglia than in
other cell types within the spinal cord, and was significantly higher
in the EPA treated group compared to the other groups. Thus,
chronic dietary EPA intake appears to increase the levels of one of
the major toxic lipid peroxidation products, resulting in increased
oxidative stress in microglia. The data clearly demonstrate that
there is a detrimental rather than a protective effect of EPA on the
progression of symptoms and the survival of G93A-SOD1 mice.
How this effect mates with the reduction of astrocytes and
microglia and the reduction of nitrotyrosine is not clear. We can
only speculate as described below that the reduction of nitrotyr-
osine by EPA may be the consequence of the reduction of
astrocytes. As concerns the microglia even if we observed a
reduction in the cell number, those remained exhibit a high toxic
lipid peroxidation which results in an increased oxidative stress
with detrimental effect on the tissue vacuolization. This observa-
tion supports data reported by other authors, which documented
significant lipid oxidation in the spinal cord of sporadic ALS
patients, and in particular a high level of 4-HHE (in astrocytes,
microglia and neurons) and a global increase in malondialdehyde
[35,36]. The study by Ilieva and collaborators (2007) showed a
selective decrease in DHA in the spinal cord of patients, paralleled
by an increase in the DHA content in the brain, which they
interpreted as a possible endogenous neuroprotective attempt. We
did not observe such changes in the tissue of our transgenic mice,
but what was notable was the different response of the tissue to
EPA supplementation: there were no notable changes overall in
the spinal cord tissue after several weeks of dietary EPA intake,
whereas there were more marked increases in the EPA and DHA
levels in the brain tissue from the same animals. Overall, the lipid
analysis showed, as expected, a predominant presence of DHA as
a fatty acid tissue component, compared to EPA. It has been
shown that this difference in brain tissue fatty acid levels may be
due to the fact that EPA is subject to rapid b-oxidation [37].
Administration of EPA after compression spinal cord injury in
rats has been shown to have significant neuroprotective effects on
neurons in the ventral horn [7]. EPA treatment has also been
shown to have beneficial effects in a mouse model of Huntington’s
disease, although the fatty acid only improved modestly motor
dysfunction, without any parallel structural evidence of neuropro-
tection [38]. There are also reports documenting the protective
effect of EPA in models of inflammation in the central nervous
system [39,40]. These observations led us to choose EPA for our
first extensive studies (although there are beneficial central nervous
system effects also reported for DHA) and hypothesize that dietary
EPA may lead to some benefits in ALS. The long chain omega-3
fatty acids EPA and DHA are safe and well-tolerated even in high
doses, and therefore could offer a large therapeutic window.
Furthermore, these fatty acids are widely and freely available (most
often as fish-oil capsules produced by various manufacturers), and
based on the favorable lay reports and specialized literature on
these compounds, ALS patients may resort to self-treatment with
omega-3 fatty acids in an attempt to modify the disease, due to
lack of effective therapies. The potential beneficial effects
advertised by health groups are also supported by positive
recommendations on these omega-3 fatty acids by the World
Health Organization. The dose of 300 mg/kg/day used in this
study was in the range of doses of DHA and EPA used in studies in
rats and mice, and is equivalent to an adult human of an average
weight of 70 kg receiving around 1.7 g of dietary EPA - if
allometric scaling to human is used, in a manner similar to that
recommended for drugs by the Food and Drug Administration
(http://www.fda.gov/), and reflecting the difference in the mouse
vs. human body surface area. Thus, the dietary EPA dose used in
the present study is well within the dose ranges of omega-3 fatty
acids used in several clinical studies, such as 24 weeks of 2.7 g
EPA/day for Crohn’s disease [41] to as high as 8 weeks of 13.5 g
EPA/day for psoriatic lesion [42]. Furthermore, it has been
recommended that athletes should consume up to 2 g EPA/day
[43]. However, it must be noted that EPA in this study was
provided in the form of the enriched Incromega oil, which
contains 70% EPA and around 10% DHA, both in the ethyl ester
forms, while the rest represented by other components. In
comparison, several groups have shown the use of ultra-pure
ethyl-EPA in clinical trials for Huntington’s disease [44]
Alzheimer’s disease [45] and depression [46].
The detection of significantly increased vacuolisation in the
G93A-SOD1 mice treated with the EPA diet compared to control
diet suggests that there is a further increased cellular damage
within the spinal cord when animals ingest this fatty acid.
Vacuolisation is associated per se with the presence of aggregates
Figure 6. Astrocyte activation in G93A-SOD1 C57BL/6 mice treated with EPA at the pre-symptomatic stage of the disease is reduced
by treatment. Some astrocytes can be observed in the wild-type littermate spinal cord (A–C). In the spinal cord of G93A-SOD1 mice, there is a
significant increase in the number of astrocytes (D–F). The treatment with EPA did not significantly alter the number of astrocytes in wild type mice
(G–I), but significantly reduced astrocytic activation in G93A-SOD1 mice (J–L) in comparison to the corresponding control group. Quantitative analysis
of astrocytic cell number (M) and staining intensity (N) in the ventral horn of the mice spinal cord: GFAP (astrocytes, red), Nissl stain (neurons, green)
and DAPI (nuclei, blue). Scale bar = 100 mm.
doi:10.1371/journal.pone.0061626.g006
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Figure 7. Microglial activation in G93A-SOD1 C57BL/6 mice treated with EPA at the pre-symptomatic stage of the disease is
reduced by EPA. Microglia can be observed in the wild type littermate spinal cord with using Iba1 and OX42 labelling (A–C). In the spinal cord of
G93A-SOD1 mice, there is a significant increase in the number of microglia (D–F). The treatment with EPA did not significantly alter the number of
microglia in the wild type (G–I), significantly reduced it in G93A-SOD1 mice (J–L) in comparison to the corresponding group on the control diet.
Quantitative analysis of microglia in the ventral horn of the spinal cord (M). Labelling shown is Iba1 (microglia, red), OX42 (activated microglia, green)
and DAPI (nuclei, blue). Scale bar = 100 mm.
doi:10.1371/journal.pone.0061626.g007
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of mutated SOD1 protein, which can occur before the onset of
significant neuronal death [47]. Unsaturated fatty acids have been
shown to promote aggregation of SOD1 mutants [48]. Therefore,
it could be suggested that the EPA obtained from the diet slowly
potentiated the aggregation of the mutated SOD1 protein and this
could ultimately result in spinal cord mitochondrial damage.
Spinal cord-specific factors appear to recruit SOD1 mutants to
spinal mitochondria [49]. SOD1 enters the mitochondria in the
demetallated form, and here it may encounter an increased
oxidative stress. Increased oxidation is reflected in the higher level
of 4-HHE detected for example in microglia in the present study.
This oxidation may favour formation of small oligomeric
aggregates, which may be the precursors of the toxic forms [50].
The mutant SOD1 localized in mitochondria could alter the
expression of essential proteins, such as the anti-apoptotic bcl-2
[51], or mitochondrial voltage dependent ion channels [52].
The tissue vacuolisation may not be directly linked to neuronal
cell loss in the first instance but may involve the non-neuronal cells
such as astrocytes and microglia. Our data showed no significant
changes in the numbers of neurons using NeuN or ChAT
immunostaining, but a significant reduction in microglia (using
Iba1 and OX42 immunostaining), and astrocytes (immunostained
with GFAP). The accumulation of high levels of the toxic lipid
oxidation product 4-HHE may endanger microglia, whose role is
complex, and likely to be a combination of positive and negative
influences on the survival of neurons. Microglia provide an
essential role in the support of neurons, and can provide a
neuroprotective role. A study has shown a significant decrease in
survival and an increase in disease progression which was
positively correlated with the reduction in microglia and astrocytes
in G93A-SOD1 mice [53]. There is much evidence that suggests a
complex and changing role of glial cells such as the microglia
during the evolution of the disease: thus, in the early stage of the
disease microglia can have an anti-inflammatory and neuropro-
tective function (e.g. defined as a M2 phenotype), which is
gradually evolving into a neurotoxic M1 phenotype in end-stage
disease [54,55]. Increased oxidative stress (increased formation of
Figure 8. Microglia in G93A-SOD1 C57BL/6 mice treated with EPA at the pre-symptomatic stage of the disease have an elevated
level of lipid oxidation. In the wild type littermates spinal cord (A–C) there is limited expression on 4-HHE. In the spinal cord of G93A-SOD1 mice,
there was an increase in the level of 4-HHE expression (D–F). The treatment with EPA did not significantly alter the level of 4-HHE in the wild type
mice (G–I), but significantly increased it in G93A-SOD1 mice (J–L) in comparison to the corresponding control group. Quantitative analysis of 4-HHE
expression in the ventral horn of the spinal cord (M). Labelling shown is Iba1 (red), 4-HHE (green) and DAPI (blue). Scale bar = 100 mm.
doi:10.1371/journal.pone.0061626.g008
Figure 9. Decreased nitrotyrosine in G93A-SOD1 C57BL/6 mice
treated with EPA at the pre-symptomatic stage of the disease.
The level of nitrotyrosine was significantly reduced in the presence of
dietary EPA compared to the control diet in G93A-SOD1 mice, but not
in wild type littermates.
doi:10.1371/journal.pone.0061626.g009
Figure 10. Increased EPA and DHA in the CNS of C57BL/6 mice
treated with EPA at the pre-symptomatic stage of the disease.
The level of DHA was significantly increased in both the brain (A) and
spinal cord (B) in the presence of dietary EPA compared to the control
diet in G93A-SOD1 mice.
doi:10.1371/journal.pone.0061626.g010
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4-HHE is a reflection of this oxidative stress) could have a critical
role in this switch from protection to toxicity. Interestingly,
imbalances in cellular antioxidant systems may be a particularly
negative factor in the evolution of the disease against the G93A
SOD1 mutation [56].
In summary, the predominant effects of dietary EPA in this
animal model of ALS are damaging rather than neuroprotective.
These observations are comparable to the disappointing and
somewhat unexpected results reported with other potentially
neuroprotective compounds or strategies, such as lithium, meth-
ylene blue or caloric restriction [20,57,58]. Therefore, the data
highlight the need to encourage extreme caution for individuals
with ALS (and especially in the context of SOD1 mutation
carriers) in the use of dietary supplements of long chain omega-3
fatty acids such as EPA. As these negative observations have
important implications for patients, a similar extensive study with
DHA is required, in our view. Our results suggest that there is a
distinct risk that prolonged exposure to preparations highly
enriched in EPA could accelerate disease progression.
Supporting Information
Figure S1 G93A-SOD1 129Sv mice with dietary EPA at the
symptomatic stage of the disease do not have a significantly
different development of the disease compared to animals on the
control diet. (A) Consumption of food, (B) The body weight of
mice, (C) Rotarod and (D) hindlimb extension reflex, and (E) grip
strength were all not affected by dietary EPA compared to control
diet.
(TIF)
Figure S2 G93A-SOD1 129Sv mice with dietary EPA at the
pre-symptomatic stage of the disease have a non-significant
exacerbation of disease phenotype compared to animals on the
control diet. (A) survival (B) disease duration, and (C) disease onset
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